1. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  2. EGFR
  3. Zanidatamab

Zanidatamab  (Synonyms: ZW 25; ZW-49 Antibody)

Cat. No.: HY-P99380 Purity: 98.56%
Technical Support

Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.

For research use only. We do not sell to patients.

CAS No. : 2169946-15-8

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Zanidatamab

Cell Proliferation/Viability Assay
WB

    Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881.  [Abstract]

    Head-to-head comparison of KJ015, Zanidatamab (0.01-100 μg/mL, 120 h), and Anbenitamab in MDA-MB-175. All assays were repeated twice.

    Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881.  [Abstract]

    Immunoblots of cell lysates from SK-Br-3 and NCI-N87 cells treated with IgG, Trastuzumab, Pertuzumab, tras+pert, or KJ015 at a final concentration of 50 nM for 24 h. Extra groups of anbenitamab and zanidatamab were added at the same concentration in MDA-MB-175 cells. Actin served as the loading control. T: trastuzumab, P: pertuzumab, T+P: tras+pert, Anbe: anbenitamab, Zani: zanidatamab.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity[1].

    Isotype

    half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3

    Recommend Isotype Controls
    Species Reactivity

    Human

    IC50 & Target[1]

    HER2

     

    In Vitro

    Zanidatamab (ZW25) has low nM binding affinity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells with a range of HER2 expression[1].
    Zanidatamab inhibits the growth of human cancer cell lines with a wide range of HER2 expression (5-54% inhibition depending on the cell line), and inhibits ligand-mediated tumor cell proliferation[1].
    Zanidatamab elicits concentration-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to 52% on TNBC cell lines expressing HER2 and exhibits synergy and additivity with multiple chemotherapeutic agents including platins, taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2 expressing tumor cell lines[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Zanidatamab (ZW25) induces significant tumor regressions, exhibiting 307% tumor growth inhibition relative to hIgG control and a 70% complete regression rate[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Gene ID

    2064  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay

    Conjugated

    Unconjugated

    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.

    Molecular Weight

    124.65kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Zanidatamab]

    Shipping

    Shipping with dry ice.

    Formulation

    Please refer to the lot-specific COA for specific buffer information.

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Format
    • half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
    Biological Activity
    • Loaded Zanidatamab on AHC2 biosensor, can bind HER2/CD340 Protein, Human (S310Y, HEK293, His, HY-P78680) with an affinity constant of 7.956E-11 M as determined in BLI assay.
    • Immobilized Zanidatamab can bind Human Her2/ERBB2 Protein (ECD, His Tag). The EC50 for this effect is 3.09 ng/mL.
    Purity & Documentation

    Purity: 98.56%

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Zanidatamab
    Cat. No.:
    HY-P99380
    Quantity:
    MCE Japan Authorized Agent: